Profile data is unavailable for this security.
About the company
LadRx Corp is a biopharmaceutical research and development company specializing in oncology. The Company focuses on the discovery, research and clinical development of anti-cancer drug candidates that employ technologies that target chemotherapeutic drugs to solid tumors and reduce off-target toxicities. The Company’s linker activated drug release (LADR) technology platform consists of an organic backbone that is attached to a chemo toxic agent. The LADR backbone is to first target and deliver the chemo toxic agent to the tumor environment, and then to release the chemo toxic agent within the tumor. The LADR Technology offers the opportunity for multiple pipeline drugs. The LADR development efforts are focused on two classes of ultra-high potency albumin-binding drugs. These LADR-based drugs, LADRs 7, 8, 9, and 10, combine the proprietary LADR backbone with derivatives of the auristatin and maytansinoid drug classes.
- Revenue in USD (TTM)0.00
- Net income in USD1.66m
- Incorporated1985
- Employees2.00
- LocationLadRx Corp11726 San Vicente Boulevard, Suite 650LOS ANGELES 90049United StatesUSA
- Phone+1 (310) 826-5648
- Fax+1 (310) 826-6139
- Websitehttps://www.ladrxcorp.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Vestiage Inc | 0.00 | -21.76k | 1.22m | 0.00 | -- | -- | -- | -- | -0.0004 | -0.0004 | 0.00 | -0.0011 | 0.00 | -- | -- | -- | -4,945.46 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -102.30 | -- | -- | -- |
| Qualigen Therapeutics Inc | 0.00 | -12.48m | 1.26m | 4.00 | -- | -- | -- | -- | -2.46 | -2.64 | 0.00 | -0.3923 | 0.00 | -- | -- | 0.00 | -118.15 | -- | -364.72 | -- | 21.30 | -- | -- | -- | -- | -7.41 | -- | -- | -- | -- | 10.22 | -- | -- | -- |
| PainReform Ltd | 0.00 | -12.54m | 1.29m | 6.00 | -- | 0.5206 | -- | -- | -7.77 | -7.77 | 0.00 | 0.9988 | 0.00 | -- | -- | 0.00 | -158.88 | -55.47 | -222.89 | -68.20 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -6.28 | -- | -- | -- |
| LadRx Corp | 0.00 | 1.66m | 1.37m | 2.00 | 0.8014 | 3.96 | 0.8170 | -- | 3.44 | 3.44 | 0.00 | 0.6973 | 0.00 | -- | -- | 0.00 | 96.28 | -58.97 | -- | -78.44 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 106.96 | -- | -- | -- |
| Lucy Scientific Discovery Inc | 16.73k | -9.76m | 1.37m | -- | -- | 16.85 | -- | 81.76 | -6.34 | -7.21 | 0.0103 | 0.046 | 0.0037 | -- | 0.7276 | -- | -215.45 | -- | -- | -- | 49.97 | -- | -58,360.55 | -- | -- | -5.10 | 0.4615 | -- | -- | -- | -53.49 | -- | -- | -- |
| Agentix Corp | 0.00 | -1.01m | 1.42m | -- | -- | -- | -- | -- | -0.0253 | -0.0253 | 0.00 | -0.071 | 0.00 | -- | -- | -- | -907.08 | -- | -- | -- | -- | -- | -- | -- | -- | -96.41 | -- | -- | -- | -- | -- | -- | -- | -- |
| Nexien Biopharma Inc | 0.00 | -246.18k | 1.43m | 0.00 | -- | -- | -- | -- | -0.0038 | -0.0038 | 0.00 | -0.0048 | 0.00 | -- | -- | -- | -679.40 | -860.53 | -- | -1,653.53 | -- | -- | -- | -- | -- | -1.77 | -- | -- | -- | -- | 42.22 | -- | -- | -- |
| Dermata Therapeutics Inc | 0.00 | -8.69m | 1.44m | 8.00 | -- | 4.46 | -- | -- | -24.67 | -24.67 | 0.00 | 0.5717 | 0.00 | -- | -- | 0.00 | -120.05 | -- | -146.08 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 18.90 | -- | -- | -- |
| 180 Life Sciences Corp | 0.00 | -16.24m | 1.46m | 4.00 | -- | -- | -- | -- | -41.54 | -41.54 | 0.00 | -1.12 | 0.00 | -- | -- | 0.00 | -176.90 | -42.39 | -354.57 | -56.41 | -- | -- | -- | -- | -- | -385.88 | -- | -- | -- | -- | 48.52 | -- | -- | -- |
| Target Group Inc | 5.64m | 228.87k | 1.48m | 46.00 | 18.46 | -- | 1.39 | 0.2626 | 0.0001 | 0.0001 | 0.0088 | -0.0115 | 0.764 | 8.60 | 124.27 | 115,104.10 | 3.10 | -37.99 | -- | -78.76 | 43.71 | -- | 4.06 | -586.97 | 0.0736 | 0.0149 | 3.10 | -- | -- | 577.83 | 92.84 | -- | -58.54 | -- |
| Bluejay Diagnostics Inc | 0.00 | -9.74m | 1.48m | 10.00 | -- | 0.4072 | -- | -- | -7.68 | -7.68 | 0.00 | 1.25 | 0.00 | -- | -- | 0.00 | -122.06 | -- | -149.68 | -- | -- | -- | -- | -- | -- | -- | 0.0048 | -- | -100.00 | -- | -7.07 | -- | -- | -- |
| Panacea Life Sciences Holdings Inc | 2.76m | -7.67m | 1.57m | 40.00 | -- | -- | -- | 0.5688 | -0.4554 | -0.4554 | 0.164 | -0.5255 | 0.1537 | 1.62 | 10.13 | 69,098.25 | -42.65 | -69.04 | -- | -225.03 | -139.49 | -181.62 | -277.51 | -505.41 | 0.0285 | -2.12 | 4.79 | -- | 46.59 | -- | 12.33 | -- | -- | -- |
| Holder | Shares | % Held |
|---|---|---|
| NBT Capital Management, Inc.as of 31 Mar 2024 | 1.00 | 0.00% |
| Armistice Capital LLCas of 31 Dec 2023 | 0.00 | 0.00% |
